Ultimately, there is some good news for diabetic people, which can decrease the painful frequency of insulin jabs born by them to control levels of blood sugar. The new long standing insulin drug degludec, administered three times a week just as effective as daily jab to control blood sugar levels.
The new insulin drug degludec gets immersed very slowly after being injected and has the potential to deal with blood glucose and lower the risk of hypoglycaemia plus glargine injections, an accessible form of insulin to control blood sugar. In order to analyze the safety and effectiveness of treatment with insulin degludec, researchers conducted a clinical trial of sixteen weeks.
The research team conscripted two hundred and fifty patient of type 2 diabetes aged eighteen to seventy years. Their levels of HbA1c- glycosylated hemoglobin was seven to eleven percent. The study subjects were arbitrarily assigned to receive insulin degludec either once a day or three times a week, or insulin gargline daily.
The results of close study showed that levels of blood sugar were same for all groups treated, with HbA1c ranging from seven to seven and half percent. Besides, it was found that rates of of hypoglycemia were low in all treatment groups but they were slightest in those who took degludec once a day.
The study revealed that five percent of the patient those received degludec daily experienced symptomatic episodes of low blood sugar in preference to thirteen percent of patients those received degludec three times a week or those assigned to glargine once a day, reported study published in the Lancet.
Due to its ultra-long action profile, insulin degludec injected three times weekly seems to give analogous glucose control to insulin glargine once daily, explained lead author Dr. Bernard Zinman of the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in Toronto.
This new basal insulin analogue might be a precious addition to clinical practice. But the safety, effectiveness and optimal use of treatment schedules for insulin degludec will require to be recognized in larger phase three trials, added Dr. Zinman. The degludec is manufactured by Novo Nordisk.